Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.63 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.63 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.63 |
| ▸ | STK16 | O75716 | 2/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.63 |
| ▸ | TYK2 | P29597 | 2/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.63 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 2/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873384 | 0.91 | CA2 (0.62) | NTRK1TBK1NUAK1STK16CSNK2A2 | |
| SCHEMBL13648535 | 0.86 | TNK2 (0.57) | IGF1RTNK2 | |
| SCHEMBL13648522 | 0.83 | IGF1R (0.53) | IGF1RTNK2 | |
| SCHEMBL4058944 | 0.83 | CA2 (0.57) | NTRK1TBK1NUAK1STK16CSNK2A2 | |
| SCHEMBL4061169 | 0.80 | CA2 (0.70) | NTRK1TBK1NUAK1STK16CSNK2A2 | |
| SCHEMBL4061436 | 0.80 | TBK1 (0.56) | NTRK1TBK1NUAK1STK16CSNK2A2 | |
| SCHEMBL3873057 | 0.79 | CA2 (0.60) | NTRK1TBK1NUAK1STK16CSNK2A2 | |
| SCHEMBL3873050 | 0.79 | STK17A (0.73) | CA2CA1CA9CDK1CDK4 | |
| SCHEMBL3447547 | 0.79 | EGFR (0.58) | IGF1R | |
| Hydrochloric Acid SCHEMBL3869305 | 0.78 | STK17A (0.71) | CA2CA1CA9CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | claimed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| EP-1392662-B1 | CDK INHIBITING PYRIMIDINES, PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | NTRK1 4205/4885TBK1 1519/4885NUAK1 345/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | NTRK1 4858/4885TBK1 3369/4885NUAK1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.